State of the Science Summit on Hematologic Malignancies

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the potential development of chimeric antigen receptor (CAR) T cells in solid tumors.

Robert Dean, MD, staff physician, Cleveland Clinic, discusses the evolution of treatment approaches in mantle cell lymphoma (MCL).

Brad Kahl, MD, discusses the rapidly evolving therapeutic landscape of CLL and the novel combinations on the horizon.

Armin Ghobadi, MD, discusses the evolution and expansion of CAR T-cell therapy in oncology and how to maximize its application across liquid and solid tumors.

Nancy L. Bartlett, MD, discusses factors in treatment decisions for patients with advanced-stage Hodgkin lymphoma.

Nancy Bartlett, MD, Koman Chair in Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses treatment regimens for patients with Hodgkin lymphoma.

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the impact of venetoclax (Venclexta) in the treatment of patients with chronic lymphocytic leukemia (CLL).

Geoffrey Uy, MD, assistant professor of medicine, Division of Oncology, Section of Bone Marrow Transplantation, Washington University School of Medicine, Siteman Cancer Center, discusses therapy selection in acute myeloid leukemia (AML).

Ravi Vij, MD, MBA, professor of medicine, Division of Oncology, Section of Bone Marrow Transplant, Washington University School of Medicine, Siteman Cancer Center, discusses the optimal induction therapy in the treatment of patients with multiple myeloma.

Stephen Oh, MD, PhD, assistant professor of medicine, Division of Hematology, Washington University School of Medicine, Siteman Cancer Center, discusses the development of JAK inhibitors in myelofibrosis.

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses the use of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia (CLL).

Jason Valent, MD, oncologist, Cleveland Clinic, discusses the potential application of minimal residual disease (MRD) negativity in patients with multiple myeloma.

Hetty Carraway, MD, oncologist, Cleveland Clinic, discusses predisposition to acute myeloid leukemia (AML).

Aaron Gerds, MD, discusses the activity and drawbacks with current systemic agents in myeloproliferative neoplasms.

Mikkael A. Sekeres, MD, discusses the characteristics of myelodysplastic syndrome and the evolving armamentarium of treatment.

Jeffrey A. Zonder, MD, discusses triplet regimens in multiple myeloma and patient eligibility for clinical trials.

Nilanjan Ghosh, MD, PhD, discusses the advances and ongoing research in frontline treatment of patients with Hodgkin lymphoma.

Saad Z. Usmani, MD, discusses the current state of immune checkpoint inhibitors in hematologic cancers, recent setbacks, and ongoing studies that could further shape the landscape.

Michael R. Grunwald, MD, discusses new and emerging agents in acute myeloid leukemia and acute lymphoblastic leukemia, as well as sequencing and toxicity challenges with these treatments.

Peter Voorhees, MD, discusses treatments for patients with early relapsed multiple myeloma and previews future research efforts.

Saad Z. Usmani, MD, clinical professor of medicine, UNC-Chapel Hill School of Medicine, chief, Plasma Cell Disorders Program, director, clinical research in hematologic malignancies, Levine Cancer Institute, discusses the evolution of PD-1/PD-L1 inhibitors in the treatment of patients with hematologic malignancies.

Nilanjan Ghosh, MD, PhD, physician, Levine Cancer Institute, discusses PET-adapted therapy in patients with Hodgkin lymphoma.

Peter Voorhees, MD, physician, Levine Cancer Institute, discusses treatments for patients with relapsed multiple myeloma.

Jing Ai, MD, physician, Levine Cancer Institute, discusses the rationale behind single-agent therapy and the development of combination therapy in patients with myelodysplastic syndrome (MDS).

Ryan W. Jacobs, MD, physician, Levine Cancer Institute, discusses the use of ibrutinib (Imbruvica) in high-risk patients with chronic lymphocytic leukemia (CLL).

Adam Waxman, MD, discusses emerging regimens for patients with multiple myeloma.

Sameh Mikhail, MD, medical oncologist, The Mark H. Zangmeister Cancer Center, discusses ongoing clinical trials for patients with myeloma.

Alfred L. Garfall, MD, MS, discussed the treatment and management of patients with multiple myeloma, with a focus on maintenance therapy, CAR T-cell therapy, and the role of transplant.

Edward A. Stadtmauer, MD, sheds light on the future of chimeric antigen receptor T-cell therapy, systemic therapeutic advances in the field of acute myeloid leukemia, and remaining challenges in the multiple myeloma paradigm.